ACO: Time to move from the description of different phenotypes to the treatable traits.

Nuria Toledo-PonsJob F M van BovenMiguel Román-RodríguezNoemí PérezJose Luis Valera FelicesJoan B SorianoBorja G Cosío

Published in: PloS one (2019)

ACO includes two conditions (smoking asthmatics and eosinophilic COPD patients) with different medication requirement and prognosis that should not be pooled together. Use of ≥300 blood eosinophils/μL as a treatable trait should be recommended.

Keyphrases

genome wide
chronic obstructive pulmonary disease
lung function
smoking cessation
healthcare
dna methylation
adverse drug
emergency department
clinical trial
cystic fibrosis
gene expression